Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT06006117 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Mosunetuzumab (SC)
DRUG: Rituximab (R)
DRUG: Bendamustine
DRUG: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
DRUG: Lenalidomide

Sponsor

The Lymphoma Academic Research Organisation